Uncovering the clinical utility of miR-143, miR-145 and miR-224 for predicting the survival of bladder cancer patients following treatment

Carcinogenesis

Volumn 36, Issue 5, 2015, Pages 528-537

  Avgeris, Margaritis ^a   Mavridis, Konstantinos ^a   Tokas, Theodoros ^b   Stravodimos, Konstantinos ^b   G Fragoulis, Emmanuel ^a   Scorilas, Andreas ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENTARY DNA; MICRORNA; MICRORNA 143; MICRORNA 145; MICRORNA 224; RNA; UNCLASSIFIED DRUG; MIRN143 MICRORNA, HUMAN; MIRN145 MICRORNA, HUMAN; MIRN224 MICRORNA, HUMAN; TUMOR MARKER;

AREA UNDER THE CURVE; ARTICLE; BLADDER CANCER; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYSTOSCOPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE OVEREXPRESSION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NON MUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; POLYADENYLATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION; RISK ASSESSMENT; STATISTICAL ANALYSIS; BLADDER; CANCER GRADING; CASE CONTROL STUDY; COMPARATIVE STUDY; GENETICS; METABOLISM; MORTALITY; MUSCLE NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR INVASION; URINARY BLADDER NEOPLASMS;

CASE-CONTROL STUDIES; FOLLOW-UP STUDIES; HUMANS; MICRORNAS; MUSCLE NEOPLASMS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84929172059     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgv024     Document Type: Article

References (57)

1. Jemal, A. et al. (2011) Global cancer statistics. CA Cancer J. Clin., 61, 69-90.
2. Ferlay, J. et al. (2014) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer.
3. Prasad, S.M. et al. (2011) Urothelial carcinoma of the bladder: definition, treatment and future efforts. Nat. Rev. Urol., 8, 631-642.
4. DeSantis, C.E. et al. (2014) Cancer treatment and survivorship statistics, 2014. CA Cancer J. Clin., 64, 252-271.
5. van Rhijn, B.W. et al. (2009) Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur. Urol., 56, 430-442.
6. Babjuk, M. et al. (2013) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur. Urol., 64, 639-653.
7. Stenzl, A. et al. (2011) Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur. Urol., 59, 1009-1018.
8. Sylvester, R.J. et al. (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol., 49, 466-475; discussion 475.
9. Svatek, R.S. et al. (2011) Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int., 107, 898-904.
10. Shariat, S.F. et al. (2007) Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. Eur. Urol., 51, 152-160.
11. Schaefer, A. et al. (2010) Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors. Nat. Rev. Urol., 7, 286-297.
12. Yoshino, H. et al. (2013) Aberrant expression of microRNAs in bladder cancer. Nat. Rev. Urol., 10, 396-404.
13. Fendler, A. et al. (2011) MicroRNAs as regulators of signal transduction in urological tumors. Clin. Chem., 57, 954-968.
14. Bartel, D.P. (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116, 281-297.
15. Filipowicz, W. et al. (2008) Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat. Rev. Genet., 9, 102-114.
16. Esquela-Kerscher, A. et al. (2006) Oncomirs-microRNAs with a role in cancer. Nat. Rev. Cancer, 6, 259-269.
17. Calin, G.A. et al. (2006) MicroRNA signatures in human cancers. Nat. Rev. Cancer, 6, 857-866.
18. Iorio, M.V. et al. (2012) MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol. Med., 4, 143-159.
19. Sachdeva, M. et al. (2009) p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc. Natl Acad. Sci. USA., 106, 3207-3212.
20. Lin, T. et al. (2009) MicroRNA-143 as a tumor suppressor for bladder cancer. J. Urol., 181, 1372-1380.
21. Noguchi, S. et al. (2013) Replacement treatment with microRNA-143 and-145 induces synergistic inhibition of the growth of human bladder cancer cells by regulating PI3K/Akt and MAPK signaling pathways. Cancer Lett., 328, 353-361.
22. Esau, C. et al. (2004) MicroRNA-143 regulates adipocyte differentiation. J. Biol. Chem., 279, 52361-52365.
23. Akao, Y. et al. (2007) Downregulation of microRNAs-143 and-145 in B-cell malignancies. Cancer Sci., 98, 1914-1920.
24. Zhu, Z. et al. (2014) MicroRNA-145 directly targets the insulin-like growth factor receptor I in human bladder cancer cells. FEBS Lett., 588, 3180-3185.
25. Law, P.T. et al. (2012) MiR-145 modulates multiple components of the insulin-like growth factor pathway in hepatocellular carcinoma. Carcinogenesis, 33, 1134-1141.
26. Cho, W.C. et al. (2011) MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1. RNA Biol., 8, 125-131.
27. Zhang, J. et al. (2013) Loss of microRNA-143/145 disturbs cellular growth and apoptosis of human epithelial cancers by impairing the MDM2-p53 feedback loop. Oncogene, 32, 61-69.
28. Chiyomaru, T. et al. (2010) miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br. J. Cancer, 102, 883-891.
29. Sachdeva, M. et al. (2010) MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res., 70, 378-387.
30. Dyrskjøt, L. et al. (2009) Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res., 69, 4851-4860.
31. Ichimi, T. et al. (2009) Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int. J. Cancer, 125, 345-352.
32. Wang, Y. et al. (2013) MicroRNA-224 targets SMAD family member 4 to promote cell proliferation and negatively influence patient survival. PLoS One, 8, e68744.
33. Liao, W.T. et al. (2013) microRNA-224 promotes cell proliferation and tumor growth in human colorectal cancer by repressing PHLPP1 and PHLPP2. Clin. Cancer Res., 19, 4662-4672.
34. Kristensen, H. et al. (2014) Hypermethylation of the GABRE~miR-452~miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy. Clin. Cancer Res., 20, 2169-2181.
35. Zhu, S. et al. (2010) Ubc9 promotes breast cell invasion and metastasis in a sumoylation-independent manner. Oncogene, 29, 1763-1772.
36. Avgeris, M. et al. (2013) The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients. Br. J. Cancer, 108, 2573-2581.
37. Mavridis, K. et al. (2013) Downregulation and prognostic performance of microRNA 224 expression in prostate cancer. Clin. Chem., 59, 261-269.
38. Livak, K.J. et al. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25, 402-408.
39. Wu, X.R. (2005) Urothelial tumorigenesis: a tale of divergent pathways. Nat. Rev. Cancer, 5, 713-725.
40. Castillo-Martin, M. et al. (2010) Molecular pathways of urothelial development and bladder tumorigenesis. Urol. Oncol., 28, 401-408.
41. Rampias, T. et al. (2014) A new tumor suppressor role for the Notch pathway in bladder cancer. Nat. Med., 20, 1199-1205.
42. Höglund, M. et al. (2001) Identification of cytogenetic subgroups and karyotypic pathways in transitional cell carcinoma. Cancer Res., 61, 8241-8246.
43. Dalbagni, G. et al. (1993) Genetic alterations in bladder cancer. Lancet, 342, 469-471.
44. Noguchi, S. et al. (2011) MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells. Cancer Lett., 307, 211-220.
45. Villadsen, S.B. et al. (2012) The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer. Br. J. Cancer, 106, 366-374.
46. Noguchi, S. et al. (2013) socs7, a target gene of microRNA-145, regulates interferon-ß induction through STAT3 nuclear translocation in bladder cancer cells. Cell Death Dis., 4, e482.
47. Peng, X. et al. (2011) Identification of miRs-143 and-145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT. PLoS One, 6, e20341.
48. Akao, Y. et al. (2007) MicroRNA-143 and-145 in colon cancer. DNA Cell Biol., 26, 311-320.
49. Pichler, M. et al. (2012) Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer. Br. J. Cancer, 106, 1826-1832.
50. Kim, T.H. et al. (2015) miR-145, targeting high-mobility group A2, is a powerful predictor of patient outcome in ovarian carcinoma. Cancer Lett., 356(2 Pt B), 937-945.
51. Slaby, O. et al. (2012) Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients. Genes Chromosomes Cancer, 51, 707-716.
52. Scisciani, C. et al. (2012) Transcriptional regulation of miR-224 upregulated in human HCCs by NF?B inflammatory pathways. J. Hepatol., 56, 855-861.
53. Li, Q. et al. (2014) miR-224 promotion of cell migration and invasion by targeting Homeobox D 10 gene in human hepatocellular carcinoma. J. Gastroenterol. Hepatol., 29, 835-842.
54. Wang, Y. et al. (2011) Role of miR-224 in hepatocellular carcinoma: a tool for possible therapeutic intervention? Epigenomics, 3, 235-243.
55. Adamopoulos, P.G. et al. (2015) miR-224 overexpression is a strong and independent prognosticator of short-term relapse and poor overall survival in colorectal adenocarcinoma. Int. J. Oncol., 46, 849-859.
56. Pignot, G. et al. (2013) microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer. Int. J. Cancer, 132, 2479-2491.
57. Puerta-Gil, P. et al. (2012) miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer. Am. J. Pathol., 180, 1808-1815.